{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-289487","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2022-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.651789+00:00","generated_at":"2026-06-21T15:27:31.460200+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva appoints Richard Francis as President and CEO effective Jan 1, 2023; Kåre Schultz to retire Dec 31, 2022","bullets":["Francis to receive $1.6M base salary, 150% target bonus, and $9M annual equity (70% PSU, 30% RSU).","Sign-on awards: $5M RSU (3-year vesting), $5M PSU (stretch goals), and $5M cash (3 installments).","Schultz to remain CEO through Dec 31, then on garden leave until Feb 19, 2023; treated as termination without cause.","Francis previously CEO of Sandoz (2014-2019) and senior exec at Biogen overseeing Tecfidera launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-289487","json":"https://secwatch.observer/filing/0001193125-22-289487.json","markdown":"https://secwatch.observer/filing/0001193125-22-289487.md","text":"https://secwatch.observer/filing/0001193125-22-289487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312522289487/0001193125-22-289487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312522289487/d284218d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:27:31.460200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26abe2acde","claim":"Kåre Schultz retired as President and Chief Executive Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD.","evidence_excerpt":"In order to facilitate an orderly transition, Kåre Schultz and the Company’s Board of Directors have mutually agreed that Mr. Schultz will retire from his current positions as President and Chief Executive Officer, and a member of the Board of Directors, effective December 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312522289487/0001193125-22-289487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"2f4c79efe1","claim":"Richard Francis was appointed as President and Chief Executive Officer at TEVA PHARMACEUTICAL INDUSTRIES LTD.","evidence_excerpt":"On November 21, 2022, Teva Pharmaceutical Industries Ltd. (the “Company”) announced that its Board of Directors had appointed Richard Francis to become the Company’s President and Chief Executive Officer, effective January 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312522289487/0001193125-22-289487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}